Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle, Manfredi Rizzo, Martin Haluzı́k, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2452-2467
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 209
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 124
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sudipta Sen, Paul Potnuru, Nadia Hernandez, et al.
JAMA Surgery (2024) Vol. 159, Iss. 6, pp. 660-660
Closed Access | Times Cited: 66
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series
Femin Prasad, Riddhita De, Vittal Korann, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 54
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Matthew Anson, Sizheng Steven Zhao, Philip Austin, et al.
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1869-1881
Open Access | Times Cited: 44
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 19
Glucagon‐like peptide‐1 receptor agonists: a narrative review of clinical pharmacology and implications for peri‐operative practice
David A. Milder, Tamara Y. Milder, S. Liang, et al.
Anaesthesia (2024) Vol. 79, Iss. 7, pp. 735-747
Open Access | Times Cited: 16
Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study
Wajd Alkabbani, Karine Suissa, KRISTINE D. GU, et al.
BMJ (2024), pp. e080340-e080340
Closed Access | Times Cited: 15
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 50
Semaglutide (GLP‐1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice
Fabiane Ferreira Martins, Thatiany de Souza Marinho, Luiz E.M. Cardoso, et al.
Cell Biochemistry and Function (2022) Vol. 40, Iss. 8, pp. 903-913
Closed Access | Times Cited: 42
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Hamlet Gasoyan, Elizabeth R. Pfoh, Rebecca Schulte, et al.
JAMA Network Open (2024) Vol. 7, Iss. 9, pp. e2433326-e2433326
Open Access | Times Cited: 13
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li, Guanzheng Yu, Huang Qi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116150-116150
Open Access | Times Cited: 10
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen, Andreas Brønden, Kristian Karstoft, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 373-382
Open Access | Times Cited: 10
Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With Human Immunodeficiency Virus
Q. Nguyen, Darcy Wooten, Daniel Lee, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 4, pp. 978-982
Closed Access | Times Cited: 10
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment
Elena Avgoustou, Ilektra Tzivaki, Γεωργία Διαμαντοπούλου, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 169-169
Open Access | Times Cited: 1
Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis
P. G. Squire, James Naude, Ali Zentner, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e089477-e089477
Open Access | Times Cited: 1
The potential role of GLP‐1 receptor agonists in osteoarthritis
M P Ryan, Saige Megyeri, Wesley Nuffer, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2025)
Closed Access | Times Cited: 1
GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications
Peyton Moore, Kevin Malone, Delena VanValkenburg, et al.
Advances in Therapy (2022) Vol. 40, Iss. 3, pp. 723-742
Closed Access | Times Cited: 37
Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials
Dimitrios Patoulias, Djordje S. Popovic, Anca Pantea Stoian, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 8, pp. 108529-108529
Closed Access | Times Cited: 20
Semaglutide in Obesity: Unmet Needs in Men
Mojca Jensterle, Manfredi Rizzo, Andrej Janež
Diabetes Therapy (2023) Vol. 14, Iss. 3, pp. 461-465
Open Access | Times Cited: 18
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
Panah Parab, Priti Chaudhary, Sonia Mukhtar, et al.
Cureus (2023)
Open Access | Times Cited: 18
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Magda Wojtara, A Mazumder, Yusra Syeda, et al.
Advances in Medicine (2023) Vol. 2023, pp. 1-7
Open Access | Times Cited: 18
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison
Carel W. le Roux, Emily R. Hankosky, Duzhe Wang, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2626-2633
Open Access | Times Cited: 17
Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes
Iurii Stafeev, Margarita Agareva, Svetlana Michurina, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176476-176476
Closed Access | Times Cited: 7
Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
David Lubasi Nalisa, Nelson Cuboia, Eman Dyab, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top